Dabigatran Etexilate Mesylate

Specification：75mg,110mg,150mg (Formulation strength)

Indications：
Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation;
Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism
Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism Following Hip Replacement Surgery

Origin：India

Batch Size：＞55kg

Registration status：
FDA：27037    A
EU：√  
CDE: Y20190000613  I

Advantage：
Inventor’s Crystal form I, the formulation which used the same API has TA in US FDA